FINWIRES · TerminalLIVE
FINWIRES

Veracyte Secures Medicare Coverage for Bladder Cancer Monitoring Test

By

Veracyte (VCYT) said Friday its TrueMRD Monitoring Test received Medicare coverage for patients with muscle-invasive bladder cancer.

The diagnostic tool is approved for tracking disease recurrence following treatment, and it detected disease return median of 131 days earlier than standard imaging during clinical studies, the company said.

The product will be commercially available for healthcare providers to order beginning June 1, Veracyte said.

Shares of the company were down 1.1% in Friday trading.

Price: $38.27, Change: $-0.63, Percent Change: -1.62%

Related Articles

Australia

Sana Biotechnology Raises $69 Million Through ATM Equity Offering

Sana Biotechnology (SANA) sold 21.6 million shares through its at-the-market equity program, raising $69 million in net proceeds, the company said Friday.The proceeds, combined with a previously disclosed $25 million investment from the Mayo Clinic, bring the company's total capital raised since the end of Q1 to $94 million, extending its cash runway into mid-2027, the company added.Shares of Sana Biotechnology were down more than 5% in recent Friday trading.Price: $2.99, Change: $-0.16, Percent Change: -4.94%

$SANA
Australia

Market Chatter: Diageo to Merge Africa, Europe Units

Diageo (DEO) will integrate its Africa and Europe operations into a single division amid an overhaul including major leadership changes, Bloomberg News reported Friday, citing an unnamed person familiar with the matter.Diageo did not immediately respond to' request for a comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $81.62, Change: $+1.05, Percent Change: +1.30%

$DEO
Australia

Vertiv Asks Shareholders to Reject Tutanota's Mini-Tender Offer

Vertiv (VRT) said Friday it is recommending that its shareholders do not tender their shares in Tutanota's "mini-tender" offer to buy up to 500,000 Vertiv shares at $410 per share.The offer price is conditional on the closing price per share of Vertiv stock exceeding $410 a share on the last trading day before the offer expires, Vertiv said, adding that unless this condition is waived by Tutanota, Vertiv shareholders who tender their shares will get a below-market price.Tutanota plans to extend the offer for successive periods of 45 to 180 days until the price of the shares is above the offer price, Vertiv said.Price: $363.20, Change: $-12.97, Percent Change: -3.45%

$VRT